CVS (CVS) Form 4 shows director stock grant at $76.04

Rhea-AI Filing Summary

CVS Health (CVS) reported a routine equity compensation transaction for a director. On 11/20/2025, a CVS director received 1,775 shares of common stock at a price of $76.04 per share. The shares were issued as payment of a semi-annual retainer under CVS Health's 2017 Incentive Compensation Plan, rather than a cash payment.

Following this grant, the director beneficially owns 13,659 shares of CVS Health common stock in direct ownership. This filing reflects standard board compensation in stock and does not describe any broader corporate or strategic change at CVS Health.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Balser Jeffrey R.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	1,775	$76.04	$135K

Holdings After Transaction: Common Stock — 13,659 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Balser Jeffrey R.

(Last) (First) (Middle)

ONE CVS DRIVE

(Street)

WOONSOCKET RI 02895

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CVS HEALTH Corp [ CVS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/20/2025		A		1,775(1)	A	$76.04	13,659	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Consists of common stock issued in payment of a semi-annual retainer, at the market price, pursuant to the Issuer's 2017 Incentive Compensation Plan.

	/s/ Jeffrey R. Balser	11/21/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the CVS (CVS) Form 4 filed for 11/20/2025 report?

The Form 4 reports that a CVS Health director received 1,775 shares of common stock on 11/20/2025 as part of the director’s compensation.

At what price were the CVS Health shares granted on 11/20/2025?

The director received 1,775 shares of CVS Health common stock at a price of $76.04 per share, issued as equity compensation.

How many CVS (CVS) shares does the reporting director own after this transaction?

After the reported transaction, the director beneficially owns 13,659 shares of CVS Health common stock, held in direct ownership.

What is the nature of this CVS Health director stock grant?

The 1,775 shares consist of common stock issued as payment of a semi-annual retainer at market price under the 2017 Incentive Compensation Plan.

Is this CVS Form 4 related to stock options or other derivatives?

No derivative securities are reported in the provided excerpt; the transaction involves non-derivative common stock granted as compensation.

Is this CVS Form 4 filed by one or multiple reporting persons?

The filing indicates it is a Form filed by one reporting person, who serves as a director of CVS Health.